Professor Sarah Parish
BSc, MSc, DPhil
Professor of Medical Statistics and Epidemiology
- MRC Programme Leader
Sarah Parish studied Mathematics at Bristol and Oxford Universities and joined the unit which became CTSU (and is now part of NDPH) in 1978. She has played a major role as a statistician in the establishment, conduct and interpretation of CTSU’s series of ground-breaking large-scale randomised trials in the treatment and prevention of cardiovascular disease. She has also been active in developing large-scale blood-based observational studies with extensive biomarker panels and genotyping. As the Director of Statistics in Vascular Trials and Genetic Epidemiology, she now leads statistical teams engaged in a spectrum of complimentary research. Her particular interests include: identifying genetic risk factors for the side-effects of common cardiovascular treatments; investigating causality in relation to factors such as adiposity and dementia that are responsible for major burdens of disease, using the large UK and China Kadoorie biobanks.
Effects of Omega-3 Fatty Acid Supplements on Arrhythmias.
Parish S. et al, (2020), Circulation, 141, 331 - 333
Investigating modifications to participant information materials to improve recruitment into a large randomized trial.
HPS2-THRIVE Collaborative Group None. et al, (2019), Trials, 20
Impact of history of vascular disease on lipoprotein(a) associations with cardiovascular outcomes: a Mendelian randomisation study in 283,658 UK Biobank participants
Stiby A. et al, (2019), EUROPEAN HEART JOURNAL, 40, 684 - 684
Risk of major gastrointestinal bleed in relation to vascular disease risk in 0.5M UK Biobank participants
Hammami I. et al, (2019), EUROPEAN HEART JOURNAL, 40, 265 - 265
Serious Adverse Effects of Extended-Release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
Haynes R. et al, (2019), Clin Ther